Clinical research with our tablet.The NYU Langone research featured here evaluated ORC-144, Orcosa’s investigational cannabidiol tablet (formerly referred to as ORAVEXX). Working with researchers at Baptist Health, the team studied its use after rotator cuff repair and followed patients’ longer-term recovery.
Published / 2022
Randomized trialAdults after arthroscopic rotator cuff repair
ORC-144 vs placebo
14-day treatment course
Early postoperative pain after rotator cuff repair
Alaia and colleagues reported a multicenter, randomized, double-blind, placebo-controlled study in adults aged 18–75, with 99 patients included in the published analysis. ORC-144 or placebo was added to standard postoperative care, including access to rescue medication.
What was observed
Patients receiving ORC-144 reported approximately 23% less pain on the first day after surgery and 22–25% greater satisfaction with pain control on the first two days, compared with placebo. No major side effects were reported.
Study context
This landmark double-blind, placebo-controlled trial demonstrated that Orcosa’s CBD tablet could reduce acute postoperative pain. The findings provide clinical evidence for ORC-144’s potential as a new non-opioid approach to pain management.
Read the publicationRead NYU Langone’s research announcementView the trial record: NCT04672252Published / 2024
Same cohortOne-year follow-up after a 14-day treatment course
82 patients analyzed
42 ORC-144 / 40 placebo
Longer-term shoulder outcomes
A follow-up publication examined recovery at least one year after surgery in patients from the original trial. Eighty-two patients were included in the analysis.
No significant differences were found between the ORC-144 and placebo groups in pain, shoulder function, satisfaction, or reoperation rates.
Study context
These findings provide further reassurance that short-term ORC-144 treatment did not compromise postoperative recovery. They add to the clinical evidence supporting its continued development as a potentially safe option for acute postoperative pain.
Read the follow-up publicationRegistered study
Investigator initiatedNCT05020028
Knee osteoarthritis
Registry updated June 9, 2026
CBD for knee osteoarthritis symptoms
A registered randomized, placebo-controlled study is evaluating CBD for symptoms of knee osteoarthritis.
The public record lists the study as recruiting, with no results posted as of its June 9, 2026 update. Visit the study record for current details.
View the trial record: NCT05020028Orcosa’s product candidates are investigational and have not been approved by the FDA. Their safety and effectiveness for the uses under investigation have not been established.
